Skip to main content
. 2012 Sep 6;4(3):873–903. doi: 10.3390/cancers4030873

Table 1.

Synergistic increase in survival by co-treatment of transgenic mouse model of PDA with PEGPH20 and gemcitabine [11].

Treatment 1 n Median Survival (days) Increase in Survival 2 (%)
Vehicle 7 10.5 0
Gemcitabine 11 15.0 43
PEGPH20 10 9.0 0
Gemcitabine + PEGPH20 11 28.5 271

1 Methods are described in Jacobetz et al. [11]; 2 Gemcitabine versus combination of gemcitabine and PEGPH20 (p = 0.002).